A fully integrated generic injectables company, Chicago-based Meitheal Pharmaceuticals (“Meitheal”), bridges critical gaps in the US healthcare market by supplying high quality, affordable generic injectables. Their diversified products, ranging from antibiotics, anticoagulants, and muscle relaxants to drugs used in chemotherapy, represent practical solutions for countless patients around the country, as well as Meitheal’s commitment to their care.
Meitheal and KinBio, a rapidly growing biopharmaceutical company based in Rehovot, Israel, are working together via a joint venture to repurpose an existing biologic. Meitheal has met with the FDA and is targeting a BLA submission for late 2023 or early 2024. The Meitheal and KinBio teams wanted to create a new corporate entity (“NewCo”) to hold the commercial intellectual property associated with this repurposed biologic. At approximately the same time as the BLA submission, an IPO is also being planned.